Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Original Paper

International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia

verfasst von: Mirjana Mitrovic, Nada Suvajdzic, Andrija Bogdanovic, Nada Kraguljac Kurtovic, Aleksandra Sretenovic, Ivo Elezovic, Dragica Tomin

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

High-hemorrhagic early death (ED) rate is a major impediment in the managing of acute promyelocytic leukemia (APL). In our group of 56 newly diagnosed APL patients, ED occurred in 12 subjects, due to endocranial bleeding (8/12), differentiation syndrome (2/12), or infection (2/12). Predictors of hemorrhagic ED were as follows: white blood cells count ≥20 × 109/L (P = 0.002337), Eastern cooperative oncology group performance status ≥3 (P = 0.00173), fibrinogen level <2 g/L (P = 0.004907), prothrombin time <50% (P = 0.0124), and International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation (ISTH DIC score) ≥6 (P = 0.00741). Multivariate analysis indicated ISTH DIC score ≥6 to be the most significant predictor for hemorrhagic ED (P = 0.008). The main finding of this study is that simple coagulation-related tests, performed on hospital admission and combined in the ISTH DIC score, might help to identify patients at high risk for fatal bleeding needing more aggressive supportive measures.
Literatur
1.
Zurück zum Zitat Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, et al. Risk adapted treatment of acute promyelocytic leukemia with all trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237–43.PubMedCrossRef Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, et al. Risk adapted treatment of acute promyelocytic leukemia with all trans retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237–43.PubMedCrossRef
2.
Zurück zum Zitat Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2009;113:1875–91.PubMedCrossRef Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2009;113:1875–91.PubMedCrossRef
3.
Zurück zum Zitat Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood. 1996;88:1390–8.PubMed Avvisati G, Lo Coco F, Diverio D, Falda M, Ferrara F, et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood. 1996;88:1390–8.PubMed
4.
Zurück zum Zitat Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128–34.PubMedCrossRef Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128–34.PubMedCrossRef
5.
Zurück zum Zitat Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118:1248–54.PubMedCrossRef Park JH, Qiao B, Panageas KS, Schymura MJ, Jurcic JG, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118:1248–54.PubMedCrossRef
6.
Zurück zum Zitat Jacomo RH, Melo RA, Souto RF, de Mattos ER, de Oliveira CT, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92:1431–2.PubMedCrossRef Jacomo RH, Melo RA, Souto RF, de Mattos ER, de Oliveira CT, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92:1431–2.PubMedCrossRef
7.
Zurück zum Zitat Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Haznedaroglu IC, et al. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res. 2010;34:317–9.CrossRef Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Haznedaroglu IC, et al. Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res. 2010;34:317–9.CrossRef
8.
Zurück zum Zitat McClellan JS, Kohrt HE, Coutre SR, Gotlib JR, Majeti R, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97:133–6.PubMedCrossRef McClellan JS, Kohrt HE, Coutre SR, Gotlib JR, Majeti R, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97:133–6.PubMedCrossRef
9.
Zurück zum Zitat De la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111:3395–402.PubMedCrossRef De la Serna J, Montesinos P, Vellenga E, Rayon C, Parody R, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111:3395–402.PubMedCrossRef
10.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620–5.PubMed Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620–5.PubMed
11.
Zurück zum Zitat Shaffer LG, Slovak ML, Campbell LJ. An international system for human cytogenetic nomenclature. Basel: Karger; 2009. Shaffer LG, Slovak ML, Campbell LJ. An international system for human cytogenetic nomenclature. Basel: Karger; 2009.
12.
Zurück zum Zitat Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease (Report of the BIOMED-1). Leukemia. 1999;13:1901–28.PubMedCrossRef Van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease (Report of the BIOMED-1). Leukemia. 1999;13:1901–28.PubMedCrossRef
13.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. ITS Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. ITS Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
14.
Zurück zum Zitat Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115:5137–46.PubMedCrossRef Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115:5137–46.PubMedCrossRef
16.
Zurück zum Zitat Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Toward definition, clinical and laboratory criteria and scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.PubMed Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Toward definition, clinical and laboratory criteria and scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.PubMed
17.
Zurück zum Zitat Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78:213–9.PubMedCrossRef Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78:213–9.PubMedCrossRef
18.
Zurück zum Zitat Kim DY, Lee JH, Lee JH, Kim SD, Lim SN, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res. 2011;35:152–8.PubMedCrossRef Kim DY, Lee JH, Lee JH, Kim SD, Lim SN, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res. 2011;35:152–8.PubMedCrossRef
19.
Zurück zum Zitat Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24–33.PubMedCrossRef Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24–33.PubMedCrossRef
20.
Zurück zum Zitat Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res. 2010;125:S51–4.PubMedCrossRef Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res. 2010;125:S51–4.PubMedCrossRef
Metadaten
Titel
International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia
verfasst von
Mirjana Mitrovic
Nada Suvajdzic
Andrija Bogdanovic
Nada Kraguljac Kurtovic
Aleksandra Sretenovic
Ivo Elezovic
Dragica Tomin
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0478-y

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.